About Nuclear envelope integral membrane protein 1
Nuclear envelope integral membrane protein 1 (NEMP1) is a protein
from Homo sapiens identified by UniProt accession
O14524, 444 residues long.
MolForge cross-references it against 0 known binders and
120 disease associations.
Target properties
| Protein name | Nuclear envelope integral membrane protein 1 |
| UniProt accession | O14524 |
| Gene | NEMP1 |
| Organism | Homo sapiens |
| Length | 444 residues |
| Molecular weight | — |
| EC numbers | — |
| Target class | UNCLASSIFIED |
| Subcellular location | — |
| Keywords | — |
Druggability
Target tractability assessment (Open Targets + pocket analysis). No approved drug
| Druggability tier | MEDIUM |
| Druggability score | — |
| Pocket score | — |
| Max clinical phase | — |
Disease associations (120)
Diseases linked to this target (Open Targets).
- eosinophil count · score 0.32
- eosinophil percentage of leukocytes · score 0.25
- apolipoprotein A 1 measurement · score 0.19
- Red cell distribution width · score 0.16
- allergic disease · score 0.15
- asthma · score 0.15
- insomnia · score 0.14
- allergic sensitization measurement · score 0.13
- Antihistamine use measurement · score 0.13
- endometriosis · score 0.13
3D Structure (1)
Experimental (PDB) and predicted (AlphaFold) structures for this protein.
| Structure | Source | Method | Mean pLDDT | Resolution (Å) |
| AF-O14524-F1 | alphafold | PREDICTED | 75.53 | — |
Amino-acid sequence (444 residues)
MAGGMKVAVS PAVGPGPWGS GVGGGGTVRL LLILSGCLVY GTAETDVNVV MLQESQVCEK RASQQFCYTN VLIPKWHDIW TRIQIRVNSS RLVRVTQVEN EEKLKELEQF SIWNFFSSFL KEKLNDTYVN VGLYSTKTCL KVEIIEKDTK YSVIVIRRFD PKLFLVFLLG LMLFFCGDLL SRSQIFYYST GMTVGIVASL LIIIFILSKF MPKKSPIYVI LVGGWSFSLY LIQLVFKNLQ EIWRCYWQYL LSYVLTVGFM SFAVCYKYGP LENERSINLL TWTLQLMGLC FMYSGIQIPH IALAIIIIAL CTKNLEHPIQ WLYITCRKVC KGAEKPVPPR LLTEEEYRIQ GEVETRKALE ELREFCNSPD CSAWKTVSRI QSPKRFADFV EGSSHLTPNE VSVHEQEYGL GSIIAQDEIY EEASSEEEDS YSRCPAITQN NFLT
Explore Nuclear envelope integral membrane protein 1 with MolForge
Find binders, run structure-based screening, and map this target across
diseases and approved drugs with our AI-powered platform.
Browse all targets